Cirqle Biomedical is a pre-clinical women’s health company aiming to expand freedom and quality of life for women everywhere. Cirqle Biomedical is developing a first-in-class non-hormonal contraceptive that is being evaluated for its potential to make cervical mucus temporarily impenetrable to sperm and thereby prevent pregnancies. Cirqle Biomedical was launched in 2019 in Copenhagen, Denmark, with backing from BioInnovation Institute (BII) and RH Capital, a San Francisco-based impact investor dedicated to women’s reproductive health.